Breast Cancer Pulse #1
Breast Cancer Pulse #1
$599.00
Publisher: BioMedTracker
- Description
- Samples
We performed a 5-question survey of 22 oncologists in the US to gauge current prescribing practices for breast cancer treatments, with a focus on HR+/HER2- recurrent or metastatic breast cancer. Drugs discussed:
•Ibrance (palbociclib, PFE)
•Afinitor (everolimus, NVS)
•Halaven (eribulin, Eisai)
•Abraxane (nab-paclitaxel, CELG)
•Doxil (pegylated liposomal doxorubicin, JNJ)
•Gemzar (gemcitabine, LLY)
•Xeloda (capecitabine, Roche)
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Actelion 
Sign up to the